The rational use of platelet transfusions in children

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 6, 1998, Pages 567-575

  Cahill, Mary R ^a   Lilleyman, John S ^b  

^a UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Childhood leukemia; Childhood thrombocytopenia; Platelets; Prophylaxis; Transfusion

Indexed keywords

THROMBOPOIETIN;

ALLOIMMUNIZATION; ANEMIA; APHERESIS; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION; LEUKEMIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 0032457958     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996056     Document Type: Review

References (95)

1. 1. Murphy MF, Waters AH. Platelet transfusions: The problem of refractoriness. Blood Rev 1990;4:16-24
2. 2. Slichter SJ. Platelet transfusion therapy. Hematol Oncul Clin North Am 1990;4:291-311
3. 3. Ogasawara K, Ueki J, Takenaka M, et al. Study on the expression of ABH antigens on platelets. Blood 1993;92:993-999
4. 4. Rebulla P. Platelet support of patients with haematological malignancies. Haematologica 1994;79:460-474
5. 5. Murphy MF, Waters AH. Clinical aspects of platelet transfusions. Blood Coagul Fibrinolysis 1991;2:389-396
6. 6. Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leucocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988;72:964-969
7. 7. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunisation using filtered blood products. Blood 1988;71:1402-1407
8. 8. Trial to Reduce Alloimmunization to Platelets Study Group. Leucocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-1869
9. 9. Sweeney JD, Holme S, Heaton WA, Nelson E. White cell reduced platelet concentrates prepared by in-line filtration of platelet rich plasma. Transfusion 1995;35:131-136
10. 10. Kao KJ, Mickel M, Braine HG, et al. White cell reduction in platelet concentrates and packed red cells by filtration: A multicentre clinical trial. The Trap Study Group. Transfusion 1995; 35:13-19
11. 11. Hathaway WE, Githens JH, Blackburn WR, et al. Aplastic anaemia, histiocytosis and erythroderma in immunologically deficient children. N Engl J Med 1965;273:953-958
12. 12. Greenbaum BH. Transfusion associated graft-versus-host disease: Historical perspective, incidence and current use of irradiated blood products. J Clin Oncol 1991;9:1889-1902
13. 13. British Committee Standards Haematology-Blood Transfusion Task Force. Guidelines on gamma irradiation of blood components for the prevention of blood transfusion associated graft versus host disease. Transfus Med 1996;6:261-271
14. 14. Roy AJ, Jaffe N, Djerassi I. Prophylactic platelet transfusions in children with acute leukaemia: A dose response study. Transfusion 1973;13:283-290
15. 15. Menitove JE, Hertenstein EG, Tse LC. Decreasing platelet concentrate dose; impact on platelet transfusion interval. Blood 1996;88(suppl I):333a.
16. 16. Dodd R. The risk of transfusion-transmitted infection. N Engl J Med 1992;327:419-420
17. 17. Donaghue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-373
18. 18. Lacritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;334: 1721-1725
19. 19. Alter HJ, Nakatsuji Y, Melpolder J, et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997;336:747-754
20. 20. Creange A, Gray F, Cesaro P, Degos J. Pooled plasma derivatives and Creutzfeldt-Jakob disease. Lancet 1996;347:482
21. 21. Flanagan P, Barbara JAJ. Prion disease and blood transfusion. Transfus Med 1996;6:213-215
22. 22. Punsalang A, Heal JM, Murphy PJ. Growth of gram-positive and gram-negative bacteria in platelet concentrates. Transfusion 1989;29:596-599
23. 23. Kothe FC, Platenkamp G-J. The use of the sterile connecting device in transfusion medicine. Transfus Med Rev 1994;8:117-122
24. 24. Hogge DE, Dutcher JP, Aisner J, et al. Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. Am J Hematol 1983;14:363-369
25. 25. Batchelor JR, Welsh KI, Burgos H. Transplantation antigens per se are poor immunogens within a species. Nature 1978;273: 54-56
26. 26. Van Eys J, Thomas D, Olivos B. Platelet use in paediatric oncology: A review of 393 transfusions. Transfusion 1978;18:169-173
27. 27. Sintnicolaas K, Vriesendorp HM, Sizoo W, et al. Delayed alloimmunisation by random single donor platelet transfusions. A randomised study to compare single donor and multiple donor platelet transfusion in cancer patients with severe thrombocytopenia. Lancet 1981,750-754
28. 28. Klingemann HG, Self S, Banaji M, et al. Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: A multivariate analysis of data from 264 cases. Br J Haematol 1987;66:115-121
29. 29. Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988;71:383-387
30. 30. Dutcher JP, Schiffer CA, Aisner J, Wiernick P. Alloimmunisation following platelet transfusion: The absence of a dose response relationship. Blood 1981;57:395-398
31. 31. Bayer WL, Bodensteiner DC, Tilzer LL, Adams ME. Use of platelets and other transfusion products in patients with malignancy. Semin Thromb Hemost 1992;18:380-391
32. 32. Hogge DE, McConnell M, Jacobson C, et al. Platelet refractoriness and alloimmunisation in paediatric oncology and bone marrow transplant patients. Transfusion 1995;35:645-652
33. 33. Wallerstein R Jr, Deisseroth AB. Use of blood and blood products for supportive care in cancer treatment. Curr Opin Oncol 1991;3:628-633
34. 34. Daly PA, Schiffer CA, Aisner J, et al. Platelet transfusion therapy: One hour post transfusion increments are valuable in predicting the need for HLA-matched preparations JAMA 1980;243:435-428
35. 35. Kickler T, Braine H, Piantadosi S, et al. A randomised, placebo-controlled trial of intravenous gammaglobulin in alloimmunised thrombocytopenic patients. Blood 1990;75:313-316
36. 36. Christie DJ, Howe RB, Lennon SS, Sauro SC. Treatment of refractoriness to platelet transfusion by protein A column therapy. Transfusion 1993;33:234-242
37. 37. National Institutes of Health Consensus Conference. Platelet transfusion therapy. JAMA 1987;257:1777-1780
38. 38. Development Task Force of the College of American Pathologists. Fresh-Frozen Plasma, Cryoprecipitate and Platelets Administration Practice Guidelines: Practice parameter for the use of fresh-frozen plasma, cryoprecipitate and platelets. JAMA 1994;271:777-781
39. 39. British Committee for Standards in Haematology, Working Party of The Blood Transfusion Task Force. Guidelines for platelet transfusions. Transfus Med 1992;2:311-318
40. 40. Ilett SJ, Lilleyman JS. Platelet transfusion requirements of children with newly diagnosed lymphoblastic leukemia. Acta Haematol 1979;62:86-89
41. 41. Aderka D, Praff G, Santo M, et al. Bleeding due to thrombocytopenia in acute leukaemias and re-evaluation of the prophylactic platelet transfusion policy. Am J Med Sci 1986;291: 147-151
42. 42. Slichter SJ, Harker LA. Thrombocytopenia: Mechanisms and management of defects in platelet production. Clinics in Haematology 1978;7:523
43. 43. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991;338:1223-1226
44. 44. Higby DJ, Cohen E, Holland JF, Sinks L. The prophylactic treatment of thrombocytopenic leukaemic patients with platelets: A double blind study. Transfusion 1974;14:440-446
45. 45. Solomon J, Bokefkamp T, Fahey JL, et al. Platelet prophylaxis in acute non-lymphoblastic leukaemia. Lancet 1978,267. Letter
46. 46. Murphy S, Litwin S, Herring LM, et al. Indications for platelet transfusion in children with acute leukaemia. Am J Hematol 1982;12:347-356
47. 47. Heckman K, Weiner GJ, Strauss RG, et al. Randomised evaluation of the optimal platelet count for prophylactic platelet transfusions in patients undergoing induction therapy for acute leukemia. Blood 1993;82(suppl 1):192a
48. 48. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997;337:1870-1875
49. 49. Quick AJ. Aspirin, platelets and haemostasis. N Engl J Med 1970;283:598. Letter
50. 50. Beutler E. Platelet transfusions: The 20,000/μl trigger. Blood 1993;81:1411-1413
51. 51. Beutler E. An iconoclastic view of conventional wisdoms in haematology. Arch Intern Med 1979;139:221-223
52. 52. Platelets for transfusion. Lancet 1972,25-26
53. 53. Ford JM. Should prophylactic platelets be given to patients with acute leukaemia? In: Lister TA, Malpas JS, eds. Platelet Transfusion. Lancaster, UK:MTP Press, 1980:45
54. th ed. Oxford: Blackwell Scientific Publications; 1993:646-647
55. 55. Blanchette VS, Hume HA, Levy GJ, et al. Guidelines for auditing pediatric transfusion practice. Am J Dis Child 1991;145:787-796
56. 56. Patten E. Controversies in transfusion medicine. Prophylactic platelet transfusion revisited after 25 years. Transfusion 1992; 32:381-385
57. 57. Strauss RG. The risks of thrombocytopenia and the standard use of platelet transfusion. Plasma Therapy and Transfusion Technology 1986;7:279-285
58. 58. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987;70: 165-172
59. 59. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651-1657
60. 60. Andrew M, Milner R, Paes B, et al. An anticoagulant dermatan sulphate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest 1992;89:321-326
61. 61. Strauss RG, Levy GJ, Sotelo-Avila C, et al. National survey of neonatal transfusion practice: II. Blood component therapy. Pediatrics 1993;91:530-536
62. 62. Chabernaud JL, Lacaze T, Zupan V, et al. Platelet transfusions in neonatology. Transfus Clin Biol 1995;1:17-25
63. 63. Andrew M, Vegh P, Caco C, et al. A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants. J Pediatr 1993;123:285-291
64. 64. Blanchette VS, Chen L, Salmonde Friedberg Z, et al. Alloimmunisation to the PLA1 platelet antigen: Results of a prospective study. Br J Haematol 1990;74:209-215
65. 65. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989, i: 363-366
66. 66. Murphy MF, Waters AH, Doughty HA, et al. Antenatal management of fetomaternal alloimmune thrombocytopenia-report of 15 affected pregnancies. Transfus Med 1994;4:281-292
67. 67. Nicolini U, Rodeck CH, Kochenour NK, et al. In utero platelet transfusion for alloimmune thrombocytopenia. Lancet 1988; ii:506
68. 68. Burrows R, Kelton J. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 1993;329:1463-1466
69. 69. Samuels P, Bussel J, Braitman L, et al. Estimation of the risk of thrombocytopenia in the offspring of pregnant women with presumed immune thrombocytopenic purpura. N Engl J Med 1990;232:229-235
70. 70. Sharon R, Tatarsky I. Low fetal morbidity in pregnancy associated with acute and chronic idiopathic thrombocytopenic purpura. Am J Hematol 1994;46:87-90
71. 71. Burrows R, Kelton J. Low fetal risk in pregnancies associated with idiopathic thrombocytopenic purpura. Am J Obstet Gynecol 1990;163,1147-1150
72. 72. Wilson J, Neame P, Kelton J. Infection-induced thrombocytopenia. Semin Thromb Hemost 1982;8:217-233
73. 73. Degos L, Tobelem G, Lethiellux P, et al. Molecular defects in platelets from patients with Bernard-Soulier syndrome. Blood 1977;50:899-903
74. 74. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: The spectrum of clinical disease. Blood 1990;75;1383-1395
75. 75. Levy-Toledano S, Tobelem G, Legrand C, et al. An acquired IgG antibody occurring in a thrombasthenic patient: Its effect on normal human platelet function. Blood 1978;51:1065-1071
76. 76. Khurana MS, Lian EC, Harkness DR. "Storage pool disease" of platelets. Association with multiple congenital cavernous haemangiomas. JAMA 1980;244:169-171
77. 77. Bolton-Maggs PHB, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet 1997;350:620-623
78. 78. Lusher JM, Iyer R. Idiopathic thrombocytopenic purpura in children. Semin Thromb Hemost 1977;3:175-199
79. 79. Bauman MA, Menitove JE, Aster RH, et al. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gamma-globulin infusion followed by platelet transfusion. Ann Intern Med 1986;104:808-809
80. 80. Harkness DR, Byrnes JJ, Lian ECY, Williams WD, Hensley GT. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 1981;246:1931-1933
81. 81. Martin DL, MacDonald KL, White KE, et al. The epidemiology and clinical aspects of hemolytic uremic syndrome in Minnesota. N Engl J Med 1990;323:1161-1167
82. 82. Wendling F, Maraskovsky E, Debill N, et al. C-MPL ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994;369: 571-574
83. 83. Lok S, Kauschansky K, Holly RD, et al. Cloning and sequencing of murine thrombopoietin and stimulation of platelet production in vivo. Nature 1994;369:565-568
84. 84. De Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-mpl ligand. Nature 1994;369:533-538
85. 85. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol conjugated recombinant human megakaryocyte growth and development factor on platelet count after chemotherapy for lung cancer. N Engl J Med 1997;336:404-409
86. 86. Goodnough LT, Kolodziei M, Ehlenbeck C, et al. A phase I study of safety and efficacy for infusible platelet membranes in patients. Blood 1995;86(suppl 1):610a
87. X) for control of bleeding in thrombocytopenic patients. Blood 1995;86(suppl 1):446a
88. 88. Ganser A, Lindemann A, Seipelt G, et al. Effects of recombinant human interleukin-3 in aplastic anaemia. Blood 1990;76: 1287-1292
89. 89. Ben-Bassat I, Douer D, Ramot B. Tranexamic acid in acute myeloid leukaemia: Possible reduction of platelet transfusions. Eur J Haematol 1990;45:86-89
90. 90. Isaacs C, Robert N, Loewy J, et al. Neumega (rhIL-II) prevents platelet transfusions in up to 4 cycles of dose-intense chemotherapy in women with breast cancer. Blood 1996;88(suppl 1):1780(Abst)
91. 91. Schiffer CA. Prophylactic platelet transfusion. Transfusion 1992; 32:295-298
92. 92. Baer MR, Bloomfield CD. Prophylactic platelet transfusion therapy: Pro. Transfusion 1992;32:377-380
93. 93. Kruskall MS. The perils of platelet transfusions. N Engl J Med 1997;337:1914-1915
94. 94. Homans A. Thrombocytopenia in the neonate. Pediatr Clin North Am 1996;43:737-755
95. 95. Manno CS. What's new in transfusion medicine? Pediatr Clin North Am 1996;43:793-756